Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)

NCT06341426 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06341426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06341426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 5, 2024
Completion date
December 28, 2026
Enrollment
92 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder, mood disorders, treatment-resistant depression